The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.

The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I):

##STR00001##

wherein X.sup.−, Z.sup.1, Z.sup.2, n, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.

The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.

Disclosed is a compound of formula (I): ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, and are as defined herein. Also disclosed are methods for increasing mammalian cell NAD.sup.+ production and improving mitochondrial cell densities comprising administering to a cell the compound or a salt thereof.

Disclosed is a compound of formula (I): ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, and are as defined herein. Also disclosed are methods for increasing mammalian cell NAD.sup.+ production and improving mitochondrial cell densities comprising administering to a cell the compound or a salt thereof.

Compounds that modulate CD73 activity, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with CD73 activity are described herein.

This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with CD73 activity, such as various cancers.

##STR00001##

This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with CD73 activity, such as various cancers.

##STR00001##

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure:

##STR00001##

Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.